drugset
drugset / Trial / NCT05046522

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

NCT05046522 ↗

Phase 3 Completed 80 enrolled RDC Clinical Pty Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy participants aged 18 years and older.

Timeline

Start
2021-09-01
Primary completion
2023-03-09
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Palmidrol Small molecule 700 mg Oral

Indications

migraine disorder